Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States

被引：0
|
作者：
Shujing Zhang
Arielle G. Bensimon
Ruifeng Xu
Ruixuan Jiang
Alexandra Greatsinger
Adina Zhang
Mizuho Fukunaga-Kalabis
Clemens Krepler
机构：
[1] Merck & Co.,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adjuvant treatment; Cost-effectiveness analysis; Pembrolizumab; Stage IIB–IIC melanoma; US health sector perspective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3038 / 3055
页数：17
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
    Zhang, Shujing
    Bensimon, Arielle G.
    Xu, Ruifeng
    Jiang, Ruixuan
    Greatsinger, Alexandra
    Zhang, Adina
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    ADVANCES IN THERAPY, 2023, 40 (07) : 3038 - 3055
  • [2] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS ADJUVANT TREATMENT FOR RESECTED STAGE IIB/IIC MELANOMA IN GREECE
    Yfantopoulos, N.
    Spanoudi, F.
    Draganigos, A.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [3] Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland
    Favre-Bulle, Andrea
    Bencina, Goran
    Zhang, Shujing
    Jiang, Ruixuan
    Andritschke, Daniel
    Bhadhuri, Arjun
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 283 - 292
  • [4] COST-EFFECTIVENESS OF PEMBROLIZUMAB AS AN ADJUVANT TREATMENT FOR ADULTS AND ADOLESCENTS AGED 12 YEARS AND OLDER WITH RESECTED STAGE IIB/ IIC MELANOMA IN FRANCE
    Saiag, P.
    Meyer, N.
    Zhang, S.
    Jiang, R.
    Mamane, C.
    Chaker, O.
    Bensimon, L.
    Babonneau, A.
    Hidra, R.
    Rey, L.
    Leproust, S.
    Rai, A.
    Vohra, D.
    Khatri, G.
    de Pouvourville, G.
    VALUE IN HEALTH, 2023, 26 (12) : S182 - S182
  • [5] Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
    Bensimon, Arielle G.
    Zhou, Zheng-Yi
    Jenkins, Madeline
    Song, Yan
    Gao, Wei
    Signorovitch, James
    Krepler, Clemens
    Liu, Frank Xiaoqing
    Wang, Jingshu
    Aguiar-Ibanez, Raquel
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 981 - 993
  • [6] Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma
    Rutkowski, Piotr
    Czarnecka, Anna M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (09) : 897 - 902
  • [7] Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma
    Long, Georgina, V
    Luke, Jason J.
    Fukunaga-Kalabis, Mizuho
    Asierto, Paolo A.
    LANCET ONCOLOGY, 2023, 24 (01): : E8 - E8
  • [8] Cost-effectiveness of human interferon-alpha as adjuvant treatment for patients with resected cutaneous malignant melanoma in stage IIB & III
    Kasteng, F.
    Stadler, R.
    Wagenius, G.
    Lundkvist, J.
    VALUE IN HEALTH, 2007, 10 (06) : A330 - A330
  • [9] Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States
    Lai, Yizhen
    Bensimon, Arielle G.
    Gao, Emily
    Bhattacharya, Rituparna
    Xu, Ruifeng
    Chevure, Jestinah
    Imai, Kentaro
    Haas, Naomi B.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : 612.e1 - 612.e11
  • [10] Adjuvant therapy for stage IIB plus IIC melanoma
    Malekzadeh, Parisa
    Brady, Mary S.
    JOURNAL OF SURGICAL ONCOLOGY, 2024, 129 (01) : 91 - 96
12345